Metaraminol

It is used to treat low blood pressure .

It is used to treat low blood pressure .

Metaraminol is contraindicated in conditions like Hypersensitivity.

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: Signs of an allergic reaction, like rash ; hives; itching ; red, swollen, blistered, or peeling skin with or without fever ; wheezing ; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat. Signs of high blood pressure like very bad headache or dizziness, passing out, or change in eyesight. A fast heartbeat . A heartbeat that does not feel normal. This medicine may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, blisters, skin sores, or leaking of fluid where the drug is going into your body.

Metaraminol should be used with caution in heart disease, thyroid disease, hypertension & diabetes. It should be used in large vein to avoid necrosis & sloughing of surrounding tissues. Cautions should be taken during pregnancy.

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

0.007 to 0.071 mg/kg (0.039 (0.039)) As recommended. IV — initial 0.028 to 0.142 mg/kg (0.085 (0.085)) As recommended. IM — As Required 0.028 to 0.142 mg/kg (0.085 (0.085)) As recommended. SC — As Required 0.214 to 1.428 mg/kg (0.82 (0.821)) As recommended. IV — Maintenace

( ) — Not recommended in this age group

( ) — Not recommended in this age group

Metaraminol is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAmphotericin BDigoxinDihydroergotamine (Mesylate)Dihydroergotamine and metaraminolhve an additive vasoconstriction effect due to alpha adrenergic agonist activity results in great increase in blood pressure.ModerateDihydroergotamine injection or nasal spray is not advised to use or if required then caution must be taken for patient tolerance.Ergotamine (Tartrate)Ergotamine significantly increases the blood pressure by synergistic vasoconstriction due to alpha adrenergic agonist activity of metaraminol.ModerateClinical monitoring of response, tolerence and excessive vasoconstriction is recommended. Patient advised to notify if numbness,tingling,muscle pain,weakness and chest pain signs appears.FurazolidoneCoadministration results hypertension and hyperpyrexia by sympathomimetic effect due to increase norepinephrine storage in neurons and increased release of catecholamine.MajorCoadministration should not be given if necessary then 14 days gap should be given during the initiation of other therapy.GuanethidineGuanethidine work by depleting catecholamines stores from adrenergic nerve endings enhance pharmacologic effect of metaraminol while decrease its hypotensive effect.ModerateMonitoring of blood pressure and heart rate is must if this combination is used.In hypertensive patients noradrenaline is used with caution.MannitolPhenelzineCoadministration involve synergistic sympathomimetic effect because metaraminol enhance noradrenaline storage in adrenergic neurons and phenelzine increased secretion of catecholamines.In some cases death has been reported.other reactions include hyperpyrexia and hypertensive reactions.MajorThis combination should not be used or give a gap of atleast 2 weeks after discontinuing phenelzine to start metaraminol.Tranylcypromine (Sulphate)Coadministration involve synergistic sympathomimetic effect because metaraminol enhance noradrenaline storage in adrenergic neurons and tranylcypromine increased secretion of catecholamines.In some cases death has been reported.MajorThis combination should not be used or give a gap of atleast 2 weeks after discontinuing tranylcypromine to start metaraminol. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Inj Store Below 30°C. Do not Freeze. Protect from Sunlight.